KRAS and colorectal carcinoma: Meagan et al. [37] investigated the interaction between SHP2 and the RAS/MAPK pathway and revealed that the co-suppression of ARS-1620 and SHP099 can lead to complete inhibition of KRAS–GTP and RAS–GTP levels in CRC cells.